When Therapeutic IgA Antibodies Might Come of Age - Sorbonne Université Access content directly
Journal Articles Pharmacology Year : 2021

When Therapeutic IgA Antibodies Might Come of Age

Abstract

Background: Extensive efforts have been made in optimizing monoclonal immunoglobulin (Ig)G antibodies for use in clinical practice. Accumulating evidence suggests that IgA or anti-FcαRI could also represent an exciting avenue toward novel therapeutic strategies. Summary: Here, we underline that IgA is more effective in recruiting neutrophils for tumor cell killing and is potently active against several pathogens, including rotavirus, poliovirus, influenza virus, and SARS-CoV-2. IgA could also be used to modulate excessive immune responses in inflammatory diseases. Furthermore, secretory IgA is emerging as a major regulator of gut microbiota, which impacts intestinal homeostasis and global health as well. As such, IgA could be used to promote a healthy microbiota in a therapeutic setting. Key messages: IgA combines multifaceted functions that can be desirable for immunotherapy.
Fichier principal
Vignette du fichier
Sterlin et Gorochov - 2021 - When Therapeutic IgA Antibodies Might Come of Age.pdf (400.78 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03139698 , version 1 (12-02-2021)

Identifiers

Cite

Delphine Sterlin, Guy Gorochov. When Therapeutic IgA Antibodies Might Come of Age. Pharmacology, 2021, 106 (1-2), pp.9-19. ⟨10.1159/000510251⟩. ⟨hal-03139698⟩
116 View
102 Download

Altmetric

Share

Gmail Facebook X LinkedIn More